Piperidine and morpholine renin inhibitors

US7858624B2 · kind B2 · utility

Assignee

• Vitae Pharmaceuticals, LLC · US

Inventors

• John J. Baldwin · Gwynedd Valley, US
• David A. Claremon · Audubon, US
• Colin M. Tice · Ambler, US
• Salvacion Cacatian · Conshohocken, US
• Lawrence Wayne Dillard · Yardley, US
• Alexey V. Ishchenko · Somerville, US
• Jing Yuan · Lansdale, US
• Zhenrong Xu · Forest Park, US
• Gerard McGeehan · Chester Springs, US
• Wei Zhao · North Potomac, US
• Robert D. Simpson · Wilmington, US
• Suresh B. Singh · Kendall Park, US

Key dates

• Filing date: Apr 5, 2007
• Grant date: Dec 28, 2010
• Expiry date: Apr 5, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D265/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.